Pharmaceutically acceptable salt of cariprazine and crystal form thereof, and preparation method therefor and use thereof

A pharmaceutically acceptable salt of cariprazine of formula I, selected from at least one of crystalline forms A, F, D, B, C, E, G and I of cariprazine embonate:

• wherein:
• an X-ray powder diffraction graph of the crystalline form A of cariprazine embonate has characteristic peaks at 2θ values of 4.8°±0.2°, 13.1°±0.2°, 18.7°±0.2°, 20.1°±0.2°, 21.0°±0.2°, and 26.1°±0.2°, wherein the cariprazine embonate is formed with cariprazine and embonic acid in a molar ratio of 1:1;
• an X-ray powder diffraction graph of the crystalline form F of cariprazine embonate has characteristic peaks at 2θ values of 4.9°±0.2°, 13.6°±0.2°, 19.2°±0.2°, 21.0°±0.2°, 24.0°±0.2°, and 26.3°±0.2°, wherein the cariprazine embonate is formed with cariprazine and embonic acid in a molar ratio of 1:1;
• an X-ray powder diffraction graph of the crystalline form D of cariprazine embonate has characteristic peaks at 2θ values of 9.6°±0.2°, 11.9°±0.2°, 16.6°±0.2°, 20.4°±0.2°, 24.5°±0.2°, and 25.3°±0.2°, wherein the cariprazine embonate is formed with cariprazine and embonic acid in a molar ratio of 1:1, and the cariprazine embonate contained about 0.67 ethanol molecules;
• an X-ray powder diffraction graph of the crystalline form B of methanol solvate of cariprazine embonate has characteristic peaks at 2θ values of 5.2°±0.2°, 10.5°±0.2°, 14.0°±0.2°, 14.4°±0.2°, 17.5°±0.2°, 21.3°±0.2°, 21.9°±0.2°, 22.9°±0.2°, and 26.2°±0.2°;
• an X-ray powder diffraction graph of the crystalline form C of acetone solvate of cariprazine embonate has characteristic peaks at 2θ values of 8.6°±0.2°, 13.0°±0.2°, 16.8°±0.2°, 17.3°±0.2°, 18.2°±0.2°, 18.5°±0.2°, 19.8°±0.2°, 22.1°±0.2°, and 23.5°±0.2°;
• an X-ray powder diffraction graph of the crystalline form E of cariprazine embonate has characteristic peaks at 2θ values of 11.0°±0.2°, 12.8°±0.2°, 13.8°±0.2°, 15.5°±0.2°, 15.9°±0.2°, 17.9°±0.2°, 18.4°±0.2°, 20.7°±0.2°, and 23.4°±0.2°;
• an X-ray powder diffraction graph of the crystalline form G of acetonitrile solvate cariprazine embonate has characteristic peaks at 2θ values of 8.7°±0.2°, 10.0°±0.2°, 13.6°±0.2°, 14.3°±0.2°, 17.5°±0.2°, 18.0°±0.2°, 20.3°±0.2°, 23.2°±0.2°, and 25.1°±0.2°;
• and
• an X-ray powder diffraction graph of the crystalline form I of acetonitrile solvate cariprazine embonate has characteristic peaks at 2θ values of 10.0°±0.2°, 14.9°±0.2°, 16.3°±0.2°, 17.7°±0.2°, 18.5°±0.2°, 19.0°±0.2°, 21.1°±0.2°, 22.1°±0.2°, and 24.5°±0.2°.